erlotinib hydrochloride has been researched along with midazolam in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (midazolam) | Trials (midazolam) | Recent Studies (post-2010) (midazolam) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 9,834 | 3,191 | 3,301 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | midazolam (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.7427 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, SD; He, P; Hidalgo, M; Li, J; Zhao, M | 1 |
| Calvert, H; Fettner, S; Hamilton, M; Ling, J; Lum, BL; Pantze, M; Plummer, R; Rakhit, A; Ranson, M; Twelves, C | 1 |
| Lin, C; Lin, G; Ma, J; Wang, S; Wang, X; Zhang, M; Zhang, Q; Zhou, Y | 1 |
| Berger, PB; Donzelli, M; Früh, M; Gillessen, S; Haschke, M; Joerger, M; Kloft, C; Krähenbühl, S; Parra-Guillen, ZP; Pfister, B; Winogradova, D | 1 |
2 trial(s) available for erlotinib hydrochloride and midazolam
| Article | Year |
|---|---|
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Erythromycin; Female; Humans; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2014 |
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Topics: Aged; Antineoplastic Agents; Caffeine; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Dried Blood Spot Testing; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Midazolam; Middle Aged; Models, Biological; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Prospective Studies; Protein Kinase Inhibitors; Substrate Specificity; Tandem Mass Spectrometry; Treatment Outcome | 2017 |
2 other study(ies) available for erlotinib hydrochloride and midazolam
| Article | Year |
|---|---|
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Topics: Anesthetics, Intravenous; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Gefitinib; Humans; Microsomes, Liver; Midazolam; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins | 2007 |
Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats.
Topics: Adjuvants, Anesthesia; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Hypoglycemic Agents; Limit of Detection; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenacetin; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tolbutamide | 2015 |